Taken together, our findings indicate that the low THCA level in plasma might enhance the clinical response and prolong the survival of combination therapy, which can predict the survival benefit for patients with HCC receiving TKIs combined with PD-1 inhibitors therapy. Here, PDCD1 is linked to hepatocellular carcinoma.